Adjuvant therapy in resected non-small cell lung cancer: current status and perspectives
Abstract Adjuvant chemotherapy increases overall survival of patients with completely resected non-small cell lung cancer. Adjuvant therapy with immune checkpoint inhibitors and tyrosine kinase inhibitors have further improved outcome in selected patients. These therapeutic achievements are discusse...
Saved in:
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Springer
2025-03-01
|
| Series: | Holistic Integrative Oncology |
| Subjects: | |
| Online Access: | https://doi.org/10.1007/s44178-024-00136-2 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Abstract Adjuvant chemotherapy increases overall survival of patients with completely resected non-small cell lung cancer. Adjuvant therapy with immune checkpoint inhibitors and tyrosine kinase inhibitors have further improved outcome in selected patients. These therapeutic achievements are discussed in the present commentary. |
|---|---|
| ISSN: | 2731-4529 |